Metabolomics Analysis on Obesity-Related Obstructive Sleep Apnea After Weight Loss Management: A Preliminary Study

• Published in: Frontiers in endocrinology (Lausanne) Vol. 12; p. 761547
• Main Authors: Huang, Weijun, Zhong, Anyuan, Xu, Huajun, Xu, Chong, Wang, Anzhao, Wang, Fan, Li, Xinyi, Liu, Yupu, Zou, Jianyin, Zhu, Huaming, Zheng, Xiaojiao, Yi, Hongliang, Guan, Jian, Yin, Shankai
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 03.01.2022
• Subjects: Adult; Endocrinology; Female; Gastric Bypass; Humans; Male; Metabolomics; Middle Aged; obesity; Obesity - complications; Obesity - surgery; obstructive sleep apnea; Roux-en-Y gastric bypass; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - metabolism; Treatment Outcome; type 2 diabetes; Weight Reduction Programs; obstructive sleep apnea; Roux-en-Y gastric bypass; type 2 diabetes; metabolomics; obesity
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2021.761547

Roux-en-Y gastric bypass (RYGB) surgery is an effective type of weight loss management and may improve obesity-related obstructive sleep apnea (OSA). Obese subjects who meet the criteria for surgery with OSA were enrolled. We investigated the metabolomic effects of RYGB on OSA. Clinical data, serum measurements including indices of glycolipid metabolism, and polysomnography (PSG) measurements were collected at baseline and 6 months after RYGB surgery. Metabolomic analysis was performed using ultra-performance liquid chromatography-mass spectrometry. A group of 37 patients with obesity, type 2 diabetes (T2DM) and suspected OSA were enrolled of which 27 were OSA subjects. After RYGB surgery, metabolic outcomes and sleep parameters were all significantly improved. The OSA remission group had lower valine, isoleucine, and C24:1(cis-15) levels, and higher trimethylamine N-oxide, hippurate, and indole-3-propionic acid levels after RYGB surgery. A combination of preoperative indices (age, apnea-hypopnea index (AHI), fasting C-peptide level, and hippurate level) predicted the RYGB effect size in obese patients with T2DM and OSA, with an area under receiver operating characteristic curve of 0.947, specificity of 82.4%, and sensitivity of 100%. RYGB surgery may significantly improve the metabolic status of patients with obesity, T2DM and OSA. A combination of preoperative indices (age, AHI, fasting C peptide level, and hippurate level) may be useful for predicting the effect size of RYGB in obese patients with T2DM and OSA. The mechanisms underlying OSA remission need to be explored.